Trial Profile
Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2017
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioGeneriX; Teva Pharmaceutical Industries
- 24 Jun 2014 New trial record